Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis?

BACKGROUND: Calcium dobesilate (CaD) is a member of the synthetic veno-active drug family. Only a small number of reports are available that describe the micro-angiogenic effects of CaD in the current literature. MATERIAL/METHODS: The antiangiogenic potential of CaD was compared with bevacizumab (Bb), which is a potent angiogenesis inhibitor, in a chick chorioallantoic membrane model. Four different concentrations (10(−7), 10(−6), 10(−5), and 10(−4) M) of drug pellet were prepared for each drug. Changes in vessel formation were scored and compared for each drug according to the previous literature. RESULT: The antiangiogenic behavior of CaD was lower than Bb, despite the significant dose-dependent manner of escalation. The anti-angiogenic scores of CaD were determined as 0.20, 0.47, 0.66, 1.0 in 10(−7), 10(−6), 10(−5), and 10(−4) M concentrations, respectively (average score >0.5 was significant). CONCLUSIONS: According to the data obtained, this agent should be used carefully for cases in which angiogenesis plays an important role in healing.